

# THE RHINOLOGIST

## 1/2024



## **Editorial Board**

**Editorial Chief:** Matteo Castelnovo

**Scientific Chief** Paolo Castelnovo, Matteo Gelardi, Alberto Macchi, Frank Rikki Canevari **Secretary:** PSA&CF srl [www.psacf.it](http://www.psacf.it)

**Editorial Staff:** Veronica Seccia, Maurizio Bignami

**Web Designer – Imaging and Marketing Chief:** Camilla Czaczkes

**Scientific Board:** Alessia Giorli, Giulia Monti, Rossana Giancaspro

**Reviewer Chief:** Ignazio La Mantia, Federico Sireci

**International Scientific Board:** Basile Landis (Switzerland), Mohammed Khalfan Said Alwashahi (Oman), Iordanis Konstantinidis (Greece)

## **Articles**

*Pg 5 - Changing in nasal cellularity in post-acute covid patients. G. Monti*

*Pg 21 - Solitary fibrous tumors of the sininasal tract: a rara case involved the nasal septum. D. Burrascano*

*Pg 26- The Elder Nose: a narrative review. E. Grigaliute*

*Pg 37- New insights into the importance of esstablishing histomorphological criteria for CRSwNP. R. Giancaspro*

*Pg 41 - Video session: Anosmia and iposmia: the cause and the solution. P.Castelnovo.*

ISSN:  
2531 – 9299



THE RHINOLOGIST  
2/2020



THE RHINOLOGIST  
1/2020



THE RHINOLOGIST  
1/2019

# THE RHINOLOGIST

*The Rhinologist is an international journal dedicated to the advancement of patient care in otolaryngology–head and neck pathology.*

*Published on behalf of the Italian Rhinology Academy (IAR), the Journal publishes original articles relating to both the clinical and basic science aspects of otolaryngology.*



Registered in Varese Court at n. 5/2016

[WWW.THERHINOLOGIST.COM](http://WWW.THERHINOLOGIST.COM)

# Authors Guidelines

The Rhinologist reserves the right to exclusive publication of all accepted manuscripts. We will not consider any manuscript previously published nor under review by another publication. Once accepted for review, the manuscript must not be submitted elsewhere. Unethical publishing, such as plagiarism, undisclosed conflicts of interest, inappropriate authorship, and duplicate publication are forbidden. This includes publication in a non-otolaryngology journal or in another language. In case of doubt, disclosure is essential and the Editor is available for consultation. Transfer of copyright to is a prerequisite of publication. All authors must sign a Copyright Transfer Agreement form.

Authors must disclose any financial relationship(s) at the time of submission, and any disclosures must be updated by the authors prior to publication. Information that could be perceived as potential conflict(s) of interest must be stated. This information includes, but is not limited to, grants or funding, employment, affiliations, patents, etc...

## Article Categories

The Rhinologist publishes the types of articles defined below. When submitting your manuscript, please follow the instructions relevant to the applicable article category. A title page, including the manuscript title and all author's full names, academic degrees, institutional affiliations, and locations. Designate one author as the corresponding author. If a paper was presented at a meeting, provide society name, city, state, country, and the exact date of the meeting.

- Original Reports
- Contemporary Reviews
- Systematic Reviews
- Case reports

**Send your article:**

**[info@therhinologist.com](mailto:info@therhinologist.com)**



**Editorial Chief:**  
Matteo Castelnuovo

**Scientific Chief:**  
Paolo Castelnuovo,  
Matteo Gelardi,  
Alberto Macchi,  
Frank Rikki Canevari

**Administrator  
and Secretary:**  
PSA&CF srl  
[www.psacf.it](http://www.psacf.it)

**Editorial Staff:**  
Veronica Seccia,  
Maurizio Bignami

**Web Designer –  
Imaging and  
Marketing Chief:**  
Camilla Czaczkes

**Scientific Board:**  
Alessia Giorli, Carlo  
Cavaliere, Giulia  
Monti

**Reviewer Chief:**  
Ignazio La Mantia,  
Federico Sireci

**International  
Scientific Board:**  
Basile Landis  
(Switzerland),  
Mohammed Khalfan  
Said Alwashahi  
(Oman), Iordanis  
Konstantinidis  
(Greece)

## Letter to the Editor

### NEW INSIGHTS INTO THE IMPORTANCE OF ESTABLISHING HISTOMORPHOLOGICAL CRITERIA FOR CRSwNP

Giancaspro Rossana<sup>1\*</sup>, Cassano Michele<sup>1</sup>, Gelardi Matteo<sup>1</sup>

1. Department of Otolaryngology, University Hospital of Foggia, Foggia, Italy

**\*Corresponding author:** Rossana Giancaspro, MD, Department of Otolaryngology, University of Foggia, Via Luigi Pinto 1, 71122, Foggia, Italy. Telephone number: +39 3293389107. Email address: [rogianca@live.it](mailto:rogianca@live.it)

**Total word count: 568**

To the Editor,

the advent of the newly developed monoclonal antibodies (mAbs) targeting type 2 (T2) inflammation has highlighted the importance of correctly typing patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP), as a function of both the endotype and phenotype, in order to identify the different clinical and biological markers associated with a poor response to conventional treatments and with an increased risk of relapse<sup>1</sup>. In this perspective, several biomarkers have been progressively identified and associated with poor prognosis in CRSwNP patients, including Charcot-Leyden crystals (CLCs), which are slender bipyramidal hexagonal crystals (~ 100 µm in maximum length) composed of Galectin-10<sup>2</sup>. As a matter of fact, CLCs are nowadays specifically considered as hallmarks of eosinophil involvement in many diseases, such as asthma, allergic rhinitis, CRSwNP, and atopic dermatitis<sup>3</sup>. However, it is still unclear how crystalline CLCs found in nasal biopsies can be used to predict CRSwNP recurrence (**Fig. 1**). Recent studies have proposed the use of histomorphology methods to define a possible cut-off of CLC in nasal polyps biopsies, such as to establish the actual risk of CRSwNP recurrence, which in turn would also be affected by the different forms of CLC<sup>4</sup>. Indeed, not only there is no unanimous histopathological criterion regarding a cut-off point to define eosinophilia in nasal polyps, but also the eosinophil count could be excessively time-costing, as even more than 500 eosinophils per high power field could be detected. On the contrary, counting CLCs might be more easy-counting.

In addition to CLCs count, we believe that histomorphology methods should aim at establishing a cut-off point for mast cells in nasal polyps' biopsies. Indeed, the great attention paid over the years

to the undoubtedly crucial role that eosinophils play in the pathogenesis of CRSwNP has led to underestimating the importance of other cells of immunophlogosis, such as mast cells, which are equally involved in the inflammatory mechanisms underlying the CRSwNP<sup>5</sup>. As a matter of fact, mast cells have been shown to be directly involved in the pathogenesis of CRSwNP, orchestrating type-2 cytokines and chemokines. Moreover, although CLCs have been traditionally considered a marker of eosinophilic inflammation, they have been shown to colocalize with both eosinophils and mast cells, thus being a marker of both cytotypes<sup>6</sup>.

Interestingly, our preliminary studies have demonstrated that mast cells infiltrate the lamina propria of almost all nasal polyps and the epithelial layer of the most difficult to treat forms. Since the intraepithelial localization of mast cells is properly related to the severity of CRSwNP, a cut-off of intraepithelial mast cells could be established to identify the most severe endotypes of CRSwNP<sup>7</sup>. This would overcome a disadvantage of CLCs counting: hematoxylin-eosin staining is complicated and requires an optimal eosin pH value to visualize the smallest CLCs. As proof of this, CLCs are rarely detected during common histological investigations. On the contrary, intraepithelial mast cell counts could be performed using May-Grunwald Giemsa staining, which is already used for nasal cytology. This staining, unlike hematoxylin-eosin, would allow to visualize all the inflammatory cells that infiltrate the nasal polyps, including mast cells, without the risk of underestimating the count (**Fig. 2**).


In light of these evidence, establish standardized histomorphological criteria that define the different forms of CRSwNP is mandatory. We believe that the keystone could be represented by intraepithelial mast cells count. For this purpose, further studies are needed to define the cut-off of infiltrating intraepithelial cells associated with increased severity of CRSwNP.

**Conflict of Interest Statement:**


The authors have no conflicts of interest to declare.

**Funding Sources:**

No funding has been received for this work



**Fig. 1** Charcot-Leyden Crystals (CLCs) in nasal polyps samples stained with hematoxylin-eosin.



**Fig. 2** Nasal polyp biopsies stained with May-Grunwald Giemsa (MGG). The arrows indicate mast cells, located in the epithelial layer (**A-C**) and in the lamina propria (**B-D**) of nasal polyps.

## REFERENCES

1. Guo, C.-L., Wang, C.-S. & Liu, Z. Clinical and biological markers in disease and biologics to treat chronic rhinosinusitis. *Curr Opin Allergy Clin Immunol* **22**, 16–23 (2022).
2. Ueki, S. *et al.* Charcot-Leyden Crystals in Eosinophilic Inflammation: Active Cytolysis Leads to Crystal Formation. *Curr Allergy Asthma Rep* **19**, 35 (2019).
3. Fu, Y.-F. *et al.* Lactose and Galactose Promote the Crystallization of Human Galectin-10. *Molecules* **28**, 1979 (2023).
4. Chen, W. *et al.* Predictive significance of Charcot-Leyden crystal structures for nasal polyp recurrence. *Clin Transl Allergy* **12**, e12212 (2022).
5. Gelardi, M., Giancaspro, R. & Cassano, M. Should the role of mast cells in chronic rhinosinusitis with nasal polyps be reevaluated? *Acta Otorhinolaryngol Ital* **41**, 576–577 (2021).
6. Gelardi, M. *et al.* Chronic rhinosinusitis with nasal polyposis (CRSwNP): the correlation between expression of Galectin-10 and Clinical-Cytological Grading (CCG). *Am J Rhinol Allergy* 19458924211049868 (2021) doi:10.1177/19458924211049867.
7. Gelardi, M., Giancaspro, R., Cassano, M. & Ribatti, D. Nasal cytology and histology in CRSwNP: Two sides of the same coin. *Frontiers in Medicine* **10**, (2023).